July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Pharmacologic and safety profile of the ocular hypotensive agent cromakalim prodrug 1 (CKLP1), a novel ATP-sensitive potassium channel opener
Author Affiliations & Notes
  • Michael P Fautsch
    Ophthalmology, Mayo Clinic, Rochester, Minnesota, United States
  • Rachel Kudgus
    Oncology, Mayo Clinic, Rochester, Minnesota, United States
  • Tommy Rinkoski
    Ophthalmology, Mayo Clinic, Rochester, Minnesota, United States
  • Cheryl Hann
    Ophthalmology, Mayo Clinic, Rochester, Minnesota, United States
  • Cindy Bahler
    Ophthalmology, Mayo Clinic, Rochester, Minnesota, United States
  • Bradley Holman
    Ophthalmology, Mayo Clinic, Rochester, Minnesota, United States
  • Joel Reid
    Oncology, Mayo Clinic, Rochester, Minnesota, United States
  • Peter Dosa
    Institute for Therapeutics Discovery and Development, Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota, United States
  • Uttio Roy Chowdhury
    Ophthalmology, Mayo Clinic, Rochester, Minnesota, United States
  • Footnotes
    Commercial Relationships   Michael Fautsch, None; Rachel Kudgus, None; Tommy Rinkoski, None; Cheryl Hann, None; Cindy Bahler, None; Bradley Holman, None; Joel Reid, None; Peter Dosa, None; Uttio Roy Chowdhury, None
  • Footnotes
    Support  NEI grant EY21727; MN Partnership for Biotechnology MNP #12.06 and TPDF #15.01; Mayo Foundation
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3772. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael P Fautsch, Rachel Kudgus, Tommy Rinkoski, Cheryl Hann, Cindy Bahler, Bradley Holman, Joel Reid, Peter Dosa, Uttio Roy Chowdhury; Pharmacologic and safety profile of the ocular hypotensive agent cromakalim prodrug 1 (CKLP1), a novel ATP-sensitive potassium channel opener. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3772. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the pharmacologic and safety parameters of CKLP1 following topical application in hound dog eyes.

Methods : Optimal concentration of CKLP1 for reduction of IOP was established in female hound dogs (n=5) by topical application to the eye with CKLP1 (5-20 mM). Following washout (14 days), the dogs were treated with the optimal dose once daily for 60 consecutive days. IOP was measured 3 times daily (1, 4 and 23 hours post treatment), 3-7 times per week. Blood pressure measurements were recorded using a tail cuff, once daily, 3-5 times per week. For pharmacokinetic studies, both eyes were treated with CKLP1 for 8 consecutive days. Blood samples were collected on days 1, 4 and 8 and concentration of CKLP1 and its parent compound levcromakalim were evaluated in the plasma by LC MS/MS. Necropsy was performed on all animals and systemic effects of drug administration were histologically evaluated in 40 different tissue samples from each animal.

Results : The 10 mM topical dose of CKLP1 was found to provide the best IOP reduction (14.4 ± 4.2 % reduction over 5 days, p=0.02) During the extended treatment regimen, 10 mM CKLP1 significantly lowered IOP by 18.9 ± 1.1 % compared to control eyes (p=0.0002) over the entire course of the study with no significant change in systolic (p=0.05) or diastolic blood pressure (p=0.26). Analysis of dog plasma showed that approximately 10% of CKLP1 was converted to its active compound levcromakalim. Half-life for CKLP1 was 318 minutes with a Cmax of 10.4 ng/ml. Area under the curve (AUC) was 5303 ng/ml x minutes. For levcromakalim, half-life was 74 minutes, Cmax was 1.2 ng/ml and AUC was 303 ng/ml x minutes. Histologic analysis did not reveal any significant finding related to drug administration.

Conclusions : Extended treatment with the ocular hypotensive agent CKLP1 showed no adverse side effects and an excellent ocular/systemic fluid and tissue safety profile. Results from this study support the use of CKLP1 in phase I clinical trials to treat ocular hypertensive diseases such as glaucoma.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×